###begin article-title 0
###xml 58 66 58 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik/NBK </italic>
A molecular analysis by gene expression profiling reveals Bik/NBK overexpression in sporadic breast tumor samples of Mexican females
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 69 74 <span type="species:ncbi:9606">women</span>
###xml 292 297 <span type="species:ncbi:9606">women</span>
Breast cancer is one of the most frequent causes of death in Mexican women over 35 years of age. At molecular level, changes in many genetic networks have been reported as associated with this neoplasia. To analyze these changes, we determined gene expression profiles of tumors from Mexican women with breast cancer at different stages and compared these with those of normal breast tissue samples.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
32P-radiolabeled cDNA was synthesized by reverse transcription of mRNA from fresh sporadic breast tumor biopsies, as well as normal breast tissue. cDNA probes were hybridized to microarrays and expression levels registered using a phosphorimager. Expression levels of some genes were validated by real time RT-PCR and immunohistochemical assays.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 231 235 231 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
We identified two subgroups of tumors according to their expression profiles, probably related with cancer progression. Ten genes, unexpressed in normal tissue, were turned on in some tumors. We found consistent high expression of Bik gene in 14/15 tumors with predominant cytoplasmic distribution.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 29 33 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
###xml 396 400 396 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
Recently, the product of the Bik gene has been associated with tumoral reversion in different neoplasic cell lines, and was proposed as therapy to induce apoptosis in cancers, including breast tumors. Even though a relationship among genes, for example those from a particular pathway, can be observed through microarrays, this relationship might not be sufficient to assign a definitive role to Bik in development and progression of the neoplasia. The findings herein reported deserve further investigation.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 141 142 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 336 337 336 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 365 366 365 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 408 409 408 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 410 411 410 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 466 467 466 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 468 469 468 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 555 556 555 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 60 65 <span type="species:ncbi:9606">women</span>
Breast cancer is one of the most frequent causes in Mexican women over 35 years of age and mortality shows a tendency to increase over time [1]. The origin and course of sporadic breast cancer are not clear. At the molecular level, some alterations have been reported as associated with this neoplasia, such as changes in DNA quantity [2], cytogenetic alterations [3], amplification of some proto-oncogenes [4,5], loss of heterozygosity in some chromosomal regions [6,7], and mutations in at least four different susceptibility genes in hereditary forms [8-11].
###end p 11
###begin p 12
The traditional way of classifying breast tumors is based on tumor size, degree of dissemination and Histopathology. Alterations in many genetic networks are involved in development of breast cancer; therefore, analysis of isolated genes is not sufficient to adequately understand this neoplasia. Transcriptional analysis of multiple genes expressed by breast tumors should provide a means to define a signature or molecular fingerprint of the disease and might progressively replace conventional diagnostic and prognostic parameters. Likewise, the capability to analyze simultaneous expression levels of thousands of genes offers better possibilities to understand and characterize the complete molecular mechanisms underlying cancer progression. Technologies such as DNA chips permit integral study of the advance of the disease, with the advantage of identifying marker genes for diagnosis, prognosis, and therapy.
###end p 12
###begin p 13
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 552 554 552 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 555 557 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
In several studies found correlations among expression profiles and clinical characteristics, estrogen receptors, lymphatic nodes or treatment response [12-16]. However, this results can not be generalized to other populations because development of this heterogeneous disease have influence from multiple factors, including age, diet, genetics, environment, geographic location, no pregnancy and race [17]. To generate portraits for each population may help in the sub-classification of tumours, prognosis, and general understanding of breast cancer [18,19] and will allow us to identify characteristic genes from the Mexican population.
###end p 13
###begin p 14
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 103 108 <span type="species:ncbi:9606">human</span>
Tumor growth rates can be <5% of those predicted by proliferation measurements alone. Several types of human cancers such as colorectal [20], ovarian [21], endometrial [22], and cervical [23], also showed an increase in apoptotic index (by TUNEL assay) during tumorigenesis, which questions if cancer research fields related with inhibition of cell death might be a critical step in cancer development. Thus, in these cases a high rate of cellular proliferation must be responsible for tumor growth.
###end p 14
###begin p 15
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 123 128 <span type="species:ncbi:9606">human</span>
Human gene expression patterns derived from cDNA microarrays have been increasingly used to identify genes associated with human cancers [12,14,24]. On the basis of these studies, it appears that cDNA microarray based gene expression analysis of breast cancers tissues would reveal molecular characteristics associated with tumorigenesis.
###end p 15
###begin p 16
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 349 353 349 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 343 348 <span type="species:ncbi:9606">human</span>
Bcl-2 family proteins contain both, anti-apoptotic and pro-apoptotic, members and are essential to maintain organ systems. For many, but not for all apoptotic signals, balance between these two Bcl-2 subfamilies determine cell fate. The pro-apoptotic Bik protein is a member of one sub-class of the Bcl-2 family designated BH3-alone [25]. The human Bik gene is located on 22q13.3 and codifies a 160 amino acid protein. Its mRNA has ubiquitous distribution with elevated levels in heart and skeletal muscle [26].
###end p 16
###begin p 17
###xml 25 29 25 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
###xml 184 186 184 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 355 365 355 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">real-time </italic>
###xml 410 418 410 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik/NBK </italic>
Recently, the product of Bik gene has been associated with tumoral reversion in different cell lines and was proposed as therapy to induce apoptosis in cancer including breast tumors [27,28]. Using cDNA microarrays, we obtained gene expression profiles of 15 breast cancers and 5 normal breast tissues. Complete pairwise comparison of selected genes with real-time RT-PCR revealed consistent overexpression of Bik/NBK gene in tumor samples.
###end p 17
###begin title 18
Methods
###end title 18
###begin title 19
Breast tissue samples
###end title 19
###begin p 20
###xml 1158 1160 1152 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
###xml 312 320 <span type="species:ncbi:9606">patients</span>
###xml 447 455 <span type="species:ncbi:9606">patients</span>
The protocol of this work was approved by the Ethical Committee of our hospital with register number 98/718/43 and all patients provided informed consent in signed letter prior to the initiation of any procedure. Samples were taken from non-affected breast tissue and affected tissue from 15 non-related Mexican patients 40 years of age [mean of 52 years and range 40-68 years]. All tumors were sporadic, infiltrating, ductal adenocarcinomas from patients who had not received adjuvant chemotherapy. Tissues were obtained from the Oncology Hospital, at the Centro Medico Nacional Siglo XXI of the Instituto Mexicano del Seguro Social in Mexico City. Each sample was snap-frozen in liquid nitrogen and stored at -70degreesC until use. Specimens were selected for analysis by two criteria: (i) sufficient material for analysis, and (ii) histological evaluation by two pathologists demonstrating that samples contained at least 70% of tumor cells (in the case of cancer samples). Representative sections from each case were paraffin-embedded for staining with haematoxylin and eosin to assess histopathologic diagnosis using American Cancer Committee criteria [29] and for their use in Immunohistochemistry assays.
###end p 20
###begin title 21
RNA extraction and mRNA purification
###end title 21
###begin p 22
###xml 67 78 67 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RNase-free </italic>
###xml 534 537 526 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
Total RNA of each sample was obtained with trizol and dissolved in RNase-free water for a final concentration of 1-2 mug/mul. Samples was stored at -70degreesC. Concentration and purity of each sample was assessed by gel electrophoresis and spectrophotometry (Ultrospec 2000, Pharmacia Biotech). Prior to obtaining poly A+ RNA, total RNA was treated with DNAse I according to Atlas pure total RNA labeling system (Clontech, Palo Alto, CA, USA). Poly A enrichment procedure was used to obtain mRNA (Atlas pure total RNA labeling system(R), Clontech, Palo Alto, CA, USA).
###end p 22
###begin title 23
Probe labeling and hybridization
###end title 23
###begin p 24
###xml 40 42 40 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
###xml 149 152 148 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 272 275 269 270 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 325 327 320 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
cDNA label procedure was used to obtain 32P-labeled cDNA from 1 mug of poly A, with MoMLV reverse transcriptase (Atlas pure total RNA labeling system(R), Clontech, Palo Alto, CA, USA). Labeled probes were purified with chroma SPIN-200 columns (Atlas cDNA Expression Arrays(R), Clontech, Palo Alto, CA, USA). Incorporation of 32P into the probe was double-checked in a scintillation counter (Beckman, model LS 9000sc).
###end p 24
###begin p 25
###xml 136 138 136 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 239 242 239 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 204 209 <span type="species:ncbi:9606">human</span>
The hybridization procedure was performed with hybridization solution mixed with the entire pool of labeled cDNA probes with > 1.25 x 106 cpm on Atlas array membrane with 609 genes, double-spotted (Atlas human cancer cDNA expression arrays(R); Clontech, Palo Alto, CA, USA). The membrane was hybridized at 68degreesC for 24 h, and then was washed with high-to-low astringency solutions. Membranes were exposed for 24 h in a phosphor screen (Kodak storage phosphor screen, Molecular Dynamics).
###end p 25
###begin title 26
Image analysis and data collection
###end title 26
###begin p 27
###xml 217 219 217 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
The digitalized image was obtained in a storm scanner (Storm 680, Molecular Dynamics, Inc.). Expression profiles were obtained with Atlas image 2.0 software (Clontech, Palo Alto, CA, USA) through comparison of normal vs. tumor tissues. We used a normalization coefficient in which average value of all genes was used to normalize the array. This coefficient was determined with the Sum method, which adds values of signal over background for all genes on arrays.
###end p 27
###begin title 28
Data analysis
###end title 28
###begin p 29
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
Hybridization profiles were analyzed with J-Express program developed and distributed by Molmine AS and collaborators [30], and Cluster and TreeView software's [31].
###end p 29
###begin title 30
Real Time-RT-PCR analysis
###end title 30
###begin p 31
###xml 497 498 495 496 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 596 600 593 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
###xml 756 761 753 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPRT </italic>
###xml 802 809 799 806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al; </italic>
###xml 815 817 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
The same source of total RNA used to define gene expression profiles was used in real time RT-PCR experiments, following all instructions outlined in the LightCycler-RNA amplification kit SYBR Green I manual (Roche Molecular Biochemicals, Mannheim, Germany). cDNA synthesis was carried out in LightCycler (Roche) in a capillary as follows: 20 mul mix reaction containing 500 ng of DNase I treated total RNA, 4 mul of LightCycler-RT-PCR reaction mix SYBR Green I (final concentration 1X), 5 mM MgCl2, 0.4 mul LightCycler-RT-PCR enzyme mix, and 5.0 pmol forward and reverse primers for both genes. Bik gene primer sequences were designed with OLIGO 4.1 and were as follows: forward 5' GAG ACA TCT TGA TGG AGA CC 3', reverse 5' TCT AAG AAC ATC CCT GAT GT 3'. HPRT gene primers were referred by Pieretti M et al; 1991 [32]. For reverse transcription, the reaction was incubated at 55degreesC for 30 min and at 95degreesC for 30 sec.
###end p 31
###begin p 32
###xml 673 674 625 626 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Amplification was carried out in the same capillary. LightCycler was programmed as follows: 50 three-segment cycles for amplification (10 sec at 95degreesC, 30 sec at 55degreesC, and acquisition (single-mode), 20 sec at 72degreesC) and three-segment cycle of product melting (0 sec at 95degreesC, 10 sec at 65degreesC, and 0 sec at 95degreesC at step-acquisition mode). Temperature transition rate for all segments of amplification cycles and melting curve cycle were set at 20degreesC/sec except for segment 3 that was set at 0.1degreesC/sec of product-melting curve analysis. Duplicate reactions were prepared for each sample along with a non-template negative control (H2O control). A standard curve was used with these assays and LightCycler3 data analysis software (Roche Molecular Biochemicals) was used in all processes.
###end p 32
###begin title 33
Immunohistochemistry
###end title 33
###begin p 34
###xml 304 309 <span type="species:ncbi:9606">human</span>
###xml 379 385 <span type="species:ncbi:9913">bovine</span>
For identification of Bik (NBK) protein expression, streptavidin-biotin peroxidase complex (DAKO LSAB Kit, Carpinteria, CA, USA) method with diaminobenzidine as chromogen was used. Epitopes were retrieved by autoclaving in 10 mM citric acid buffer, pH 6.1 for 2 min. As primary antibody, polyclonal anti-human NBK/Bik FL-160 (Santa Cruz Biotechnology, work dilution 1:100) in 1% bovine serum albumin-phosphate buffered saline (BSA-PBS) was used. Formalin-fixed, paraffin-embedded sections of normal skin epithelium served as positive controls for Bik (NBK). Negative control slides were processed in parallel, omitting primary antibody.
###end p 34
###begin title 35
Results
###end title 35
###begin title 36
Expression profiles of normal and malignant breast specimens
###end title 36
###begin p 37
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 380 390 380 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Euclidean </italic>
###xml 497 576 497 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NCK5AI, CDK5 activator, CDC25A, ERK4, K2P, COL11A1, OBCAM, AMPHIREGULIN, BCGF1 </italic>
###xml 580 584 580 584 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMP8</italic>
###xml 70 75 <span type="species:ncbi:9606">human</span>
We analyzed gene expression patterns in dissected normal or malignant human breast tissue from 20 individuals, 15 infiltrating ductal carcinomas, nine stage II, six stage III, and five normal breast samples. Hierarchical cluster analysis was used to group genes on the basis of similarity in their patterns of expression. We used average cluster linkage, uncentered [31] based on Euclidean distance and removed all genes that were turned on in tumors but that were not expressed in normal tissue (NCK5AI, CDK5 activator, CDC25A, ERK4, K2P, COL11A1, OBCAM, AMPHIREGULIN, BCGF1 and BMP8).
###end p 37
###begin p 38
###xml 63 64 63 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 415 491 415 491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IFNGR2, interleukin 2, laminin B1, MSH2, MSH6 CASP8 and 10, RB1, PCNA, EGFR </italic>
###xml 495 499 495 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGS2</italic>
###xml 553 566 553 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MIF, CDK 2, 5</italic>
###xml 572 585 572 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink">7, RPSA, JUP </italic>
###xml 589 594 589 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ITGAE</italic>
###xml 674 689 674 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CASP 10, CD30-L</italic>
###xml 695 703 695 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD-40-L </italic>
###xml 717 770 717 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras-like small, FGF 3 and 5, TDGF1, ERK5, MIF, IFNGR2</italic>
###xml 772 814 772 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MIG, IFN-alpha, beta, gamma, IL-3, -4, -9 </italic>
###xml 818 828 818 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-13, IP-10</italic>
###xml 830 875 830 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPRT, DCC, TEK, netrin-2, cadherins 4, 8, 12 </italic>
###xml 879 882 879 882 <italic xmlns:xlink="http://www.w3.org/1999/xlink">13 </italic>
###xml 883 885 883 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 888 904 888 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMP3, 8, 10, 12 </italic>
###xml 908 911 908 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink">13 </italic>
###xml 932 965 932 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL11A2, CCNG1, CDC-6, ATM, N-MYC</italic>
###xml 971 974 971 974 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
Cluster analysis of tumors and controls is described in Figure 1. Patterns of gene expression among tumors showed great variation (Figure 1A); however, we identified two main groups. The left branch is conformed by four histologic type II and one type III, while the right branch contains five type II and five type III. Left branch shows distinctive underexpression and loss of expression areas with genes such as IFNGR2, interleukin 2, laminin B1, MSH2, MSH6 CASP8 and 10, RB1, PCNA, EGFR and PGS2, among others, and a few overexpressed genes such as MIF, CDK 2, 5, and 7, RPSA, JUP and ITGAE. On the other hand, right branch shows overexpression areas with genes such as CASP 10, CD30-L, and CD-40-L (TNF family), ras-like small, FGF 3 and 5, TDGF1, ERK5, MIF, IFNGR2, MIG, IFN-alpha, beta, gamma, IL-3, -4, -9 and -13, IP-10, HPRT, DCC, TEK, netrin-2, cadherins 4, 8, 12 and 13 [33], MMP3, 8, 10, 12 and 13 (metalloproteinase), COL11A2, CCNG1, CDC-6, ATM, N-MYC, and p53.
###end p 38
###begin p 39
###xml 10 12 10 12 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 581 599 581 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAK, BAX, BIK, BAD</italic>
###xml 627 653 627 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCL2, BCLW, MCL1, BCL2- A1</italic>
###xml 715 722 715 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BIK/NBK</italic>
###xml 855 860 855 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCL1 </italic>
In Figure 1B, tumors and controls were associated in a dendrogram obtained with expression profile of each sample. With this analysis, tumors were separated in two main branches; left group contained five tumors defined predominantly by histologic type II, while right group was composed by stage II and III tumors, at the same percentage. In the lower part of the same Figure, we showed the gene expression pattern of eight genes related with apoptotic process obtained from each tumor, showing changes across all samples but exposing the possible relation between pro-apoptotic (BAK, BAX, BIK, BAD) and anti-apoptotic genes (BCL2, BCLW, MCL1, BCL2- A1). We showed that pro-apoptotic BCL2-interacting killer gene (BIK/NBK) overexpressed in nearly all samples (14/15), which makes it a possible candidate for further studies on its role in breast cancer. MCL1 was underexpressed or missing, at least 93.3% (14/15), relative to controls.
###end p 39
###begin p 40
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
Due to consistent high expression of Bik gene in breast cancer, we validated its overexpression by real-time PCR and studied distribution of Bik protein in tumor breast samples by Immunohistochemistry.
###end p 40
###begin title 41
Real time RT-PCR assay for Bik gene
###end title 41
###begin p 42
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
###xml 78 83 78 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPRT </italic>
###xml 113 114 113 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 173 177 173 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
###xml 181 186 181 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPRT </italic>
###xml 536 541 536 541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPRT </italic>
###xml 707 711 707 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
According to the Methods section, we developed real-time RT-PCR using Bik and HPRT mRNAs as templates. In Figure 2, we showed amplification products of different samples of Bik and HPRT genes. With real-time RT-PCR, results of 9/13 samples (69%) agreed with those obtained through microarray analysis (considering NB and T14) and in 31% of tumors, we were unable to confirm the result. By using melting curves (data not shown), we confirmed that amplification products obtained with real-time RT-PCR were specific. As positive control, HPRT gene (housekeeping) was used (samples numbers 11 and 14) for tumors and normal breast (NB). We used tumor 14 as negative control (tumor that wich show expression for Bik gene in microarray assay).
###end p 42
###begin title 43
Characterization of Bik/NBK expression by immunohistochemistry
###end title 43
###begin p 44
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3D</xref>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
After RT-PCR analysis, we checked the distribution and abundance of Bik protein on slides obtained from the same tissue used for histopathologic diagnosis. Only in poorly or well-differentiated tumor areas we found presence of BIK protein with predominant cytoplasmic location (Figure 3A). Figures 3C and 3D (magnification to 400x) show Bik protein in a sample of breast cancer. Presence of BIK protein was specific because, when primary antibody was omitted, we did not observe any signal in neoplasic tissue (Figure 3B).
###end p 44
###begin title 45
Discussion
###end title 45
###begin p 46
Advances in high-density DNA microarray technology have permitted to screen large numbers of genes and to correlate tumoral stages and gene-expression profiles in cancer research. The idea is that tumor behavior is ruled by expression of hundreds of genes; thus microarrays analysis allows those behaviors and clinical features to be predicted. In the present study, 10 genes were turned on in some tumors respect to the normal tissue.
###end p 46
###begin p 47
###xml 201 202 201 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 937 942 <span type="species:ncbi:9606">human</span>
With microarray analysis of samples, we identified two subgroups probably related with cancer progression. In the first group, we identified an underexpression area (lower part of dendrogram in Figure 1) Wich corresponded to four histological stage II tumors, (T2, T5, T12 and T14) and one tumor in histological stage III, (T3). The latter tumor probably corresponded to a stage II tumor at molecular level because its profile expression was similar to others in the same group. We think that this group belongs to an initial stage of development of neoplasia, because it presents fewer alterations than the second group, and because the behavior of some genes related with the beginning of tumor development such as genes related with DNA repairment, apoptosis, TNF, Fas-L route, checkpoint, remodeling, and maintenance of extracellular matrix, were underexpressed or lost their expression while other genes were overexpressed, such as human macrophage migration inhibitory factor and some cyclin-dependent kinases and cytoskeletal proteins.
###end p 47
###begin p 48
###xml 25 26 25 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 197 205 197 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL11A2 </italic>
###xml 209 218 209 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">netrin-2 </italic>
###xml 294 298 294 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCC </italic>
###xml 302 313 302 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cadherin 13</italic>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
The right branch (Figure 1) contains stage II or III tumors and probably correspond to more advanced stages of progression of neoplasia. In this group, we found some overexpressed genes; of these, COL11A2 and netrin-2 had not been previously associated with breast cancer. Other genes, such as DCC and cadherin 13, were found overexpressed in our samples but underexpressed in other reports [34]; these genes probably have mutations that differentially affect their proteins.
###end p 48
###begin p 49
###xml 567 569 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 764 766 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 930 932 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
Apoptosis is a mechanism to control cell death which occurs during normal development, growth, and maintenance in multicellular organisms. It can be activated by stimulation of a cell surface death receptor or release of cytochrome c from mitochondria. In the cascade of events initiated by this signaling, cysteine aspartyl proteases, or caspases are cleaved from an inactive zymogen to an active heterodimer. These active caspases degrade several components critical for cell survival, such as DNA repair elements, structural proteins, and cell signaling peptides [35]. Caspase-3, the primary death effector, serves as a key target for monitoring apoptosis, for it is activated through both cell surface death receptor and mitochondrial release of cytochrome c [36]. Disruption in signaling pathways that regulate apoptosis can lead to a variety of pathologic conditions, making apoptosis an area of intense focus for research [37].
###end p 49
###begin p 50
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 145 149 145 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
###xml 193 199 193 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCL-1 </italic>
###xml 667 671 667 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
Eight genes related with apoptosis are found in the lower part of Figure 1B. Only two genes showed differential expression in nearly all tumors, Bik gene was overexpressed in 14/15 samples and MCL-1 gene expression was diminished or absent in the same number of tumors. The behavior of the remaining genes was not constant; in tumor 5, for example, nearly all selected genes were overexpressed, whereas in tumor 6 expression of nearly all selected genes was lost. The heterogeneous behavior of these genes makes it difficult to establish their role in apoptosis or survival of neoplasic cells. However, it was possible to establish which genes, as in the case of the Bik gene, are probably related with cancer progression or are involved in other genetic networks.
###end p 50
###begin p 51
###xml 541 576 541 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bad, Bik/Nbk, Bid, Bim/Bod, and Bmf</italic>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 705 713 705 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nbk/Bik </italic>
###xml 843 847 843 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nbk </italic>
###xml 891 894 891 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bax</italic>
###xml 896 900 896 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nbk </italic>
###xml 915 922 915 922 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl-xL </italic>
###xml 926 932 926 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl-2 </italic>
###xml 945 948 945 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bax</italic>
###xml 972 976 972 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nbk </italic>
###xml 1051 1055 1051 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bak </italic>
###xml 1098 1102 1098 1102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nbk </italic>
###xml 1103 1105 1103 1105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
BH3-only proteins are structurally distant members of the Bcl-2 protein family which triggers apoptosis. These proteins share with each other and with the remainder of the Bcl-2 family only a nine amino acid BH3 (Bcl-2 Homology) region. This domain is required for its ability to bind to Bcl-2-like, pro-survival proteins and to initiate apoptosis. Mammals have at least 10 BH3-only genes that differ in expression pattern and model of activation (regulated by a diverse range of transcription factors). Certain BH3-only proteins, including Bad, Bik/Nbk, Bid, Bim/Bod, and Bmf, are restrained by post-translational modifications that cause their sequestration from pro-survival Bcl-2 family members [38]. Nbk/Bik (natural-born killer/Bcl-2-interacting killer) is a tissue-specific BH3-only protein which molecular function is largely unknown. Nbk fails to induce apoptosis in the absence of Bax. Nbk interacts with Bcl-xL and Bcl-2 but not with Bax. It was suggested that Nbk acts as an indirect killer which triggers Bax-dependent apoptosis, whereas Bak is not sufficient to confer sensitivity to Nbk [39].
###end p 51
###begin p 52
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bax </italic>
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bak </italic>
###xml 187 191 187 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bid </italic>
###xml 194 198 194 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bim </italic>
###xml 241 245 241 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bak </italic>
###xml 249 253 249 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bax </italic>
###xml 296 300 296 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bad </italic>
###xml 304 308 304 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
###xml 333 337 333 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bax </italic>
###xml 340 343 340 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bak</italic>
###xml 564 567 564 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bax</italic>
###xml 569 572 569 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bak</italic>
###xml 578 587 578 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bad-like </italic>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
BH3-only proteins require multidomain pro-apoptotic members Bax and Bak to release cytochrome c from mitochondria and kill cells. Short peptides representing alpha-helical BH3 domains of Bid or Bim are capable of inducing oligomerization of Bak and Bax to release cytochrome c. BH3 peptides from Bad and Bik cannot directly activate Bax or Bak, but instead bind anti-apoptotic members of BCL-2, resulting in displacement of Bid-like BH3 domains which initiate mitochondrial dysfunction. These data support two types of BH3 domains: Bid-like domains which activate Bax, Bak, and Bad-like domains which sensitize by occupying the pocket of anti-apoptotic members [40].
###end p 52
###begin p 53
###xml 105 109 105 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
###xml 243 247 243 247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 814 816 814 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1059 1061 1059 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
Bik, a BH3-alone protein (Bcl-2 homology domain), is a pro-apoptotic member of the BCL2 family. Missense Bik gene mutations and sequence alterations in intronic regions were observed in cell lymphomas; these data indicate that mutation of the Bik gene is relatively frequent [41,42]. The importance of phosphorylation and desphosphorylation reactions in intracellular signaling pathways has long been accepted. The importance of serine/threonine protein phosphatases in many processes including apoptosis is recognized. The phosphorylation state of anti-apoptotic (Bcl-2 and Bcl-xL) and pro-apoptotic (Bad, Bid and Bik) Bcl-2 proteins regulates their cellular activity and, therefore, cell survival and cell death. For instance, desphosphorylation of Bad allows it to interact with Bcl-xL and initiate cell death [43]. However, mutation of the Bik phosphorylation sites, in which the Thr and Ser residues were changed to alanine residues, reduced the apoptotic activity of Bik protein without significantly affecting its ability to heterodimerize with BCL-2 [44]
###end p 53
###begin p 54
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 354 356 354 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
Of note, a significant fraction of either ectopic or endogenous BIK was found associated with the endoplasmic reticulum, suggesting that this organelle, in addition to mitochondria, may be a target of BIK function [45]. Collectively, the results identify BIK as an initiator of cytochrome c release from mitochondria operating from a location at the ER [46]. These results indicate that any function of Bik in programmed cell death and stress-induced apoptosis must overlap that of other BH3-only proteins [47].
###end p 54
###begin p 55
###xml 23 27 23 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 196 203 196 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al; </italic>
###xml 248 254 248 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CUL-5 </italic>
###xml 447 451 447 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
###xml 483 485 483 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 601 605 601 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
###xml 649 656 649 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al; </italic>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 686 690 686 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
###xml 751 758 751 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al; </italic>
###xml 764 766 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 625 630 <span type="species:ncbi:9606">human</span>
Because the product of Bik gene is pro-apoptotic, this protein has been used to induce apoptosis in several cancer cell lines (PC-3, HT-29, MCF-7, MDA-MB-231, 435, 468 and A540) [27,28,48]. Fay M et al; in 2003 [49] reported underexpression of the CUL-5 gene in breast tumor tissue, whereas expression levels in several cancer cell lines (MCF7, MDA-MB-231) are essentially identical to those of normal breast. Probably breast tumor tissues (i.e., Bik gene) have a different behavior vs. breast cancer cell lines at a molecular level. Moreover we found some reports with different expression levels of Bik gene among multiple human tissues: Daniel T et al; 1999 [48] reported absence of Bik expression in heart, skeletal muscle, and brain, while Verma et al; 2000 [26] reported higher expression in heart and skeletal muscle. It is difficult to reconcile these reports.
###end p 55
###begin title 56
Conclusion
###end title 56
###begin p 57
###xml 24 28 24 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
It is not known whether Bik gene works as an apoptosis activator or only sensitizes the cell for death. In any event, it could be a prognostic factor and a possible therapy target in breast cancer. The findings reported in this paper deserve further investigation.
###end p 57
###begin title 58
List of abbreviations
###end title 58
###begin p 59
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ATM </italic>
ATM Ataxia telangiectasia
###end p 59
###begin p 60
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAD </italic>
BAD BCL2-antagonist of cell death
###end p 60
###begin p 61
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAK </italic>
BAK BCL2-antagonist/killer 1
###end p 61
###begin p 62
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BAX </italic>
BAX BCL2-associated x protein
###end p 62
###begin p 63
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCGF1 </italic>
BCGF1 B-cell growth factor
###end p 63
###begin p 64
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCL2- A1 </italic>
BCL2- A1 BCL2-related protein A1
###end p 64
###begin p 65
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCL2 </italic>
BCL2 B-cell CLL/lymphoma 2
###end p 65
###begin p 66
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bcl-xL </italic>
Bcl-xL BCL2-like 1
###end p 66
###begin p 67
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CUL-5 </italic>
CUL-5 Cullin 5
###end p 67
###begin p 68
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BCLW </italic>
BCLW BCL2-like 2
###end p 68
###begin p 69
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik/Nbk </italic>
Bik/Nbk BCL2-interacting killer/ natural-born killer
###end p 69
###begin p 70
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BMP8 </italic>
BMP8 Bone morphogenetic protein 8
###end p 70
###begin p 71
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CASP10 </italic>
CASP10 Apoptotic cysteine protease MCH4
###end p 71
###begin p 72
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CASP8 </italic>
CASP8 Apoptotic cysteine protease MCH5
###end p 72
###begin p 73
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CCNG1 </italic>
CCNG1 Cyclin G1
###end p 73
###begin p 74
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD30-L </italic>
CD30-L CD30 ligand
###end p 74
###begin p 75
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CD-40-L </italic>
CD-40-L CD40 ligand
###end p 75
###begin p 76
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDC25A </italic>
CDC25A Cell division cycle 25a
###end p 76
###begin p 77
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDC-6 </italic>
CDC-6 CDC6-related protein
###end p 77
###begin p 78
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDK 2 </italic>
CDK 2 Cyclin-dependent kinase 2
###end p 78
###begin p 79
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDK 5 </italic>
CDK 5 Cell division protein kinase 5
###end p 79
###begin p 80
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDK 7 </italic>
CDK 7 Cyclin-dependent kinase 7
###end p 80
###begin p 81
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CDK5 activator </italic>
CDK5 activator Cyclin-dependent kinase 5 activator p35
###end p 81
###begin p 82
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL11A1 </italic>
COL11A1 Collagen type xi alpha-1
###end p 82
###begin p 83
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COL11A2 </italic>
COL11A2 Collagen type xi alpha-2
###end p 83
###begin p 84
cpm Counts per million
###end p 84
###begin p 85
DCC Tumor suppressor protein DCC
###end p 85
###begin p 86
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">EGFR </italic>
EGFR Epidermal growth factor receptor
###end p 86
###begin p 87
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERK4 </italic>
ERK4 Extracellular signal-regulated kinase 4
###end p 87
###begin p 88
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ERK5 </italic>
ERK5 Extracellular signal-regulated kinase 5
###end p 88
###begin p 89
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGF 3 </italic>
FGF 3 Fibroblast growth factor-3
###end p 89
###begin p 90
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGF 5 </italic>
FGF 5 Fibroblast growth factor-5
###end p 90
###begin p 91
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPRT </italic>
HPRT Hypoxanthine-guanine phosphoribosyltransferase
###end p 91
###begin p 92
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IFN-alpha </italic>
IFN-alpha Interferon alpha-c leukocyte
###end p 92
###begin p 93
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IFN-beta </italic>
IFN-beta Interferon beta-1
###end p 93
###begin p 94
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IFN-gamma </italic>
IFN-gamma Interferon gamma
###end p 94
###begin p 95
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IFNGR2 </italic>
IFNGR2 Interferon gamma accessory factor-1
###end p 95
###begin p 96
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-13 </italic>
IL-13 Interleukin-13
###end p 96
###begin p 97
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-3 </italic>
IL-3 Interleukin-3
###end p 97
###begin p 98
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-4 </italic>
IL-4 Interleukin-4
###end p 98
###begin p 99
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IL-9 </italic>
IL-9 Interleukin-9
###end p 99
###begin p 100
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IP-10 </italic>
IP-10 IFN-gamma-inducible chemokine IP-10
###end p 100
###begin p 101
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ITGAE </italic>
ITGAE Integrin alphae
###end p 101
###begin p 102
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JUP </italic>
JUP Junction plakoglobin
###end p 102
###begin p 103
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K2P </italic>
K2P Keratin, type ii cytoskeletal 2 oral
###end p 103
###begin p 104
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MCL1 </italic>
MCL1 Myeloid cell leukemia sequence 1
###end p 104
###begin p 105
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MIF </italic>
MIF Macrophage migration inhibitory factor
###end p 105
###begin p 106
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MIF </italic>
MIF Macrophage migration inhibitory factor
###end p 106
###begin p 107
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MIG </italic>
MIG Gamma interferon induced monokine
###end p 107
###begin p 108
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMP10 </italic>
MMP10 Matrix metalloproteinase 10
###end p 108
###begin p 109
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMP12 </italic>
MMP12 Matrix metalloproteinase 12
###end p 109
###begin p 110
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMP13 </italic>
MMP13 Matrix metalloproteinase 13
###end p 110
###begin p 111
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMP3 </italic>
MMP3 Matrix metalloproteinase 3
###end p 111
###begin p 112
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMP8 </italic>
MMP8 Matrix metalloproteinase 8
###end p 112
###begin p 113
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MSH2 </italic>
MSH2 DNA mismatch repair protein MSH2
###end p 113
###begin p 114
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MSH6 </italic>
MSH6 DNA mismatch repair protein MSH6
###end p 114
###begin p 115
NB Normal breast
###end p 115
###begin p 116
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NCK5AI </italic>
NCK5AI Cyclin-dependent kinase 5 activator isoform p39i
###end p 116
###begin p 117
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-MYC </italic>
N-MYC N-MYC proto-oncogene
###end p 117
###begin p 118
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OBCAM </italic>
OBCAM Opioid binding cell adhesion molecule
###end p 118
###begin p 119
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
p53 cellular tumor antigen p53
###end p 119
###begin p 120
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCNA </italic>
PCNA Proliferating cell nuclear antigen
###end p 120
###begin p 121
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGS2 </italic>
PGS2 Dermatan sulfate proteoglycan core protein
###end p 121
###begin p 122
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ras-like small </italic>
ras-like small Ras-like small GTPase TTF
###end p 122
###begin p 123
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RB1 </italic>
RB1 Retinoblastoma susceptibility
###end p 123
###begin p 124
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RPSA </italic>
RPSA Laminin 37kd receptor
###end p 124
###begin p 125
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TDGF1 </italic>
TDGF1 Teratocarcinoma-derived growth factor
###end p 125
###begin p 126
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TEK </italic>
TEK TYROSINE-PROTEIN KINASE RECEPTOR
###end p 126
###begin p 127
TNF Tumor necrosis factor
###end p 127
###begin p 128
BH3 Bcl-2 Homology
###end p 128
###begin p 129
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bid </italic>
Bid BH3 interacting domain death agonist
###end p 129
###begin p 130
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bim/Bod </italic>
Bim/Bod Bcl-2 like11 (apoptosis facilitator)
###end p 130
###begin p 131
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bmf </italic>
Bmf Bcl-2 modifying factor
###end p 131
###begin title 132
Competing interests
###end title 132
###begin p 133
The author(s) declare that they have no competing interests.
###end p 133
###begin title 134
Authors' contributions
###end title 134
###begin p 135
NG performed microarrays and real-time RT-PCR assays, contributed toward the design of the study and drafted the manuscript. FS participated in the conception and design of the study. HA performed real-time RT-PCR and immunohistochemistry assays. ECQ participated in the conception and design study. IA obtained and performed histopathologic diagnosis of the samples. RP participated in the conception of the study. DA drafted the manuscript, participated in the conception and design of study and its coordination. All authors read and approved the final manuscript.
###end p 135
###begin title 136
Pre-publication history
###end title 136
###begin p 137
The pre-publication history for this paper can be accessed here:
###end p 137
###begin p 138

###end p 138
###begin title 139
Acknowledgements
###end title 139
###begin p 140
This work was supported by grants No. 34451-M and Salud-2003-C01-074 from Mexican Council of Science and Technology (CONACYT) and by the Medical Research Council of Mexican Social Security Institute (IMSS) FOFOI FP-0038/1248; FP-0038/1247; FP-0038/763 Mexico. The authors would like to thank PhD Jose Moreno (Specialties Hospital), PhD Guadalupe Rico (Pediatrics Hospital) for technical cooperation, M.A. Maggie Brunner (Managing Editor, Archives of Medical Research) for technical English assess, National Medical Center Century-XXI, IMSS, and PhD Juan Burgueno to assessment on statistical approach. E Curiel-Quesada is a COFAA fellow.
###end p 140
###begin article-title 141
Sistema Unico de Informacion para la Vigilancia Epidemiologica /DGE/SSA. Incidencia de casos nuevos de enfermedades por grupo de edad Estados Unidos Mexicanos
###end article-title 141
###begin article-title 142
###xml 32 37 <span type="species:ncbi:9606">human</span>
Fractional allelic imbalance in human breast cancer increases with tetraploidization and chromosome loss
###end article-title 142
###begin article-title 143
Chromosome analysis of 97 primary breast carcinomas: identification of eight karyotypic subgroups
###end article-title 143
###begin article-title 144
ERBB2 amplification in breast cancer with a high rate of proliferation
###end article-title 144
###begin article-title 145
c-myc amplification is an independent prognostic factor in postmenopausal breast cancer
###end article-title 145
###begin article-title 146
Genetic alterations in breast cancer
###end article-title 146
###begin article-title 147
Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters
###end article-title 147
###begin article-title 148
BRCA1 mutations in primary breast and ovarian carcinomas
###end article-title 148
###begin article-title 149
Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13
###end article-title 149
###begin article-title 150
Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families
###end article-title 150
###begin article-title 151
ATM mutations in cancer families
###end article-title 151
###begin article-title 152
###xml 23 28 <span type="species:ncbi:9606">human</span>
Molecular portraits of human breast tumours
###end article-title 152
###begin article-title 153
Gene expression profiling of primary breast carcinomas using arrays of candidate genes
###end article-title 153
###begin article-title 154
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
###end article-title 154
###begin article-title 155
The future of cytotoxic therapy: selective cytotoxicity based on biology is the key
###end article-title 155
###begin article-title 156
Expression profiling of small cellular samples in cancer: less is more
###end article-title 156
###begin article-title 157
###xml 68 73 <span type="species:ncbi:9606">human</span>
###xml 78 83 <span type="species:ncbi:10090">mouse</span>
Chipping away at breast cancer: insights from microarray studies of human and mouse mammary cancer
###end article-title 157
###begin article-title 158
[Microarray technology--potential in cancer research]
###end article-title 158
###begin article-title 159
Classification of cancers by expression profiling
###end article-title 159
###begin article-title 160
###xml 32 37 <span type="species:ncbi:9606">human</span>
Detection of apoptotic cells in human colorectal cancer by two different in situ methods: antibody against single-stranded DNA and terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) methods
###end article-title 160
###begin article-title 161
###xml 65 70 <span type="species:ncbi:9606">human</span>
Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers
###end article-title 161
###begin article-title 162
Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium
###end article-title 162
###begin article-title 163
p53, Bcl-2, PCNA expression, and apoptotic rates during cervical tumorigenesis
###end article-title 163
###begin article-title 164
###xml 112 117 <span type="species:ncbi:9606">human</span>
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors
###end article-title 164
###begin article-title 165
The Bcl-2 protein family: arbiters of cell survival
###end article-title 165
###begin article-title 166
###xml 27 32 <span type="species:ncbi:9606">human</span>
Structural analysis of the human pro-apoptotic gene Bik: chromosomal localization, genomic organization and localization of promoter sequences
###end article-title 166
###begin article-title 167
The pro-apoptotic protein, Bik, exhibits potent antitumor activity that is dependent on its BH3 domain
###end article-title 167
###begin article-title 168
Systemic tumor suppression by the proapoptotic gene bik
###end article-title 168
###begin article-title 169
Bioinformatics software solutions. J-Express
###end article-title 169
###begin article-title 170
TreeView & Cluster
###end article-title 170
###begin article-title 171
Absence of expression of the FMR-1 gene in fragile X syndrome
###end article-title 171
###begin article-title 172
###xml 91 96 <span type="species:ncbi:9606">human</span>
H-cadherin, a novel cadherin with growth inhibitory functions and diminished expression in human breast cancer
###end article-title 172
###begin article-title 173
p53, proliferating cell nuclear antigen, and Ki-67 expression in extrauterine leiomyosarcomas
###end article-title 173
###begin article-title 174
Mammalian caspases: structure, activation, substrates, and functions during apoptosis
###end article-title 174
###begin article-title 175
Emerging roles of caspase-3 in apoptosis
###end article-title 175
###begin article-title 176
Neurodegenerative disorders and ischemic brain diseases
###end article-title 176
###begin article-title 177
Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins
###end article-title 177
###begin article-title 178
Induction of cell death by the BH3-only Bcl-2 homolog Nbk/Bik is mediated by an entirely Bax-dependent mitochondrial pathway
###end article-title 178
###begin article-title 179
Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics
###end article-title 179
###begin article-title 180
###xml 29 34 <span type="species:ncbi:9606">human</span>
Mutations of the BIK gene in human peripheral B-cell lymphomas
###end article-title 180
###begin article-title 181
Serine/threonine protein phosphatases in apoptosis
###end article-title 181
###begin article-title 182
Phosphorylation of the pro-apoptotic protein BIK: mapping of phosphorylation sites and effect on apoptosis
###end article-title 182
###begin article-title 183
Induction and endoplasmic reticulum location of BIK/NBK in response to apoptotic signaling by E1A and p53
###end article-title 183
###begin article-title 184
BH-3-only BIK functions at the endoplasmic reticulum to stimulate cytochrome c release from mitochondria
###end article-title 184
###begin article-title 185
Proapoptotic BH3-only Bcl-2 family member Bik/Blk/Nbk is expressed in hemopoietic and endothelial cells but is redundant for their programmed death
###end article-title 185
###begin article-title 186
###xml 189 193 <span type="species:ncbi:10090">mice</span>
Expression of the death gene Bik/Nbk promotes sensitivity to drug-induced apoptosis in corticosteroid-resistant T-cell lymphoma and prevents tumor growth in severe combined immunodeficient mice
###end article-title 186
###begin article-title 187
Analysis of CUL-5 expression in breast epithelial cells, breast cancer cell lines, normal tissues and tumor tissues
###end article-title 187
###begin title 188
Figures and Tables
###end title 188
###begin p 189
###xml 0 85 0 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Dendrogram and picture of hierarchical cluster of 15 mammary tumors and normal tissue</bold>
Dendrogram and picture of hierarchical cluster of 15 mammary tumors and normal tissue. Expression profiles from tumor and normal tissue (average from five normal tissues) were obtained through average-linkage, hierarchical, uncentered clustering analysis, as described in Methods. Genes unexpressed in normal tissue were not included in analysis. In dendrograms, each branch corresponds to similar expression profile among genes (A) or samples (B). Green squares in picture correspond to normal expression levels. Yellow squares correspond to absence of expression. Black squares correspond to underexpressed genes. Red squares correspond to overexpressed genes. Picture under dendrogram in panel details behavior of eight apoptosis-related genes along samples.
###end p 189
###begin p 190
###xml 42 46 42 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPRT </italic>
###xml 0 60 0 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Real time RT-PCR validation of expression <italic>Bik </italic>and <italic>HPRT </italic>genes</bold>
###xml 86 90 86 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bik </italic>
###xml 107 112 107 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HPRT </italic>
Real time RT-PCR validation of expression Bik and HPRT genes. Amplification curves of Bik (Bik T1 to T14), HPRT (T11 and T14) and non-affected breast (NB) mRNAs are shown. Graphic generated by LightCycler-based real time PCR thermocycler. The abscissa shows fluorescence relative units and ordinate cycle number.
###end p 190
###begin p 191
###xml 0 65 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Distribution of Bik protein in mammary ducts from adenocarcinomas</bold>
###xml 277 284 <span type="species:ncbi:9606">patient</span>
Distribution of Bik protein in mammary ducts from adenocarcinomas. Anti-Bik/NBK polyclonal antibody) was reacted with HRP-secondary antibody and revealed with DAB. Haematoxylin was used as counter stain. A, C, and D are different tumor areas. B, negative control from the same patient.
###end p 191

